<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05062525</url>
  </required_header>
  <id_info>
    <org_study_id>VIVACIOUS</org_study_id>
    <secondary_id>21-5797</secondary_id>
    <nct_id>NCT05062525</nct_id>
  </id_info>
  <brief_title>Immune Response to COVID-19 Vaccine in Immunotherapy (IO) and Non-IO Treated Cancer Patients</brief_title>
  <acronym>VIVACIOUS</acronym>
  <official_title>Immune Response to COVID-19 Vaccine in Immunotherapy (IO) and Non-IO Treated Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of antibody response against SARS-CoV-2 vaccination in patients treated with&#xD;
      IO-treatment, in comparison with antibody titers in patients treated with non-IO treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood samples will be analyzed to determine the magnitude of SARS-CoV-2 immunity in cancer&#xD;
      patients treated with immunotherapy by quantifying antibodies and other tumor or blood-based&#xD;
      biomarkers against SARS-CoV-2 epitopes following vaccination. We will also explore for&#xD;
      potential development of autoantibodies and other blood-based biomarkers, following&#xD;
      SARS-CoV-2 vaccination, and their correlation with clinical manifestation of IO related&#xD;
      immune-related adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2021</start_date>
  <completion_date type="Actual">September 28, 2021</completion_date>
  <primary_completion_date type="Actual">September 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of SARS-CoV-2 antibodies</measure>
    <time_frame>15 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of immune-related adverse events</measure>
    <time_frame>15 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">53</enrollment>
  <condition>COVID-19</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Immunotherapy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Immunotherapy</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with solid malignancies treated with either immunotherapy or non-immunotherapy&#xD;
        treatment who have received the SARS-CoV-2 vaccination.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with solid malignancies treated with either IO or non-IO treatment.&#xD;
&#xD;
          2. All categories of IO treatment allowed (immune-checkpoint inhibitors, bi-specific T&#xD;
             cell engagers, cytokine agonists and others), as well as all categories of non-IO&#xD;
             treatment (such as chemotherapy and targeted therapies). These can be given as part of&#xD;
             standard of care or within participation in a clinical trial.&#xD;
&#xD;
          3. Patients are allowed to have any of the approved vaccines in Canada, such as Pfizer,&#xD;
             Moderna, AstraZeneca or their approved combinations.&#xD;
&#xD;
          4. Patients must receive all appropriate doses of SARS-CoV-2 vaccination, as dictated by&#xD;
             the respective vaccine schedules.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 29, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19 Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

